Identifiers
Functions
Regulatory treatment varies by market. In the EU, the substance is covered by ECHA C&L notifications, indicating aggregated GHS hazard communication from company reports. In Australia, it is listed on the AICIS inventory of industrial chemicals. In New Zealand, it lacks individual approval but may be used as a component under a group standard. The US entry references the New Zealand EPA status, not a US-specific regulation. Product category matters: industrial chemical listings do not automatically cover cosmetic or drug uses, so each market's category-specific rules apply separately.
1 regulation
Regulatory records
| Entry | Regulation | Type | Status |
|---|---|---|---|
| 8747 | Inventory of Existing Cosmetic Ingredients in China (IECIC) I | List I | authorized |
Record details
1 regulation
Chemical: L-Lysine, N-(1-oxohexadecyl)glycyl-L-histidyl-
1 regulation
L-Lysine, N-(1-oxohexadecyl)glycyl-L-histidyl-: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
The most decision-relevant conditions are inventory status and hazard communication. In New Zealand, the substance is not approved as a standalone chemical but may be used in a product under a group standard, which imposes conditions on that product's composition and use. In the EU, GHS classification notifications imply obligations for labeling and safety data sheets. No exposure limits or specific quantitative thresholds were provided. The molecular formula and identifiers are fixed, but they do not determine permissible concentrations. Compliance hinges on the specific product category and the applicable group standard or notification requirements.
Before launch assessment, confirm the substance's regulatory status in each target market. For New Zealand, verify that the finished product falls under an applicable group standard and that the substance is used only as a component, not as a standalone chemical. For the EU, ensure GHS classification and labeling align with the aggregated C&L notifications. For Australia, confirm the AICIS inventory listing covers the intended use. Documentation should include the substance's identifiers (CAS 147732-56-7, EC 680-607-0) and any product-specific approvals. No evidence of pre-market authorization or registration was provided.
The available regulatory position is insufficient to support a launch decision because it only covers industrial chemical inventory status and GHS notifications. It does not address cosmetic, drug, or food-use regulations, which are likely more restrictive. The New Zealand group standard allowance is conditional and product-specific, but the conditions are not detailed. The EU C&L notification is not an approval for use. No exposure limits, concentration limits, or safety assessment data were provided. Therefore, a compliance decision cannot be made solely on this evidence; additional market-specific and category-specific regulatory review is required.
No recent regulatory changes or effective dates were provided in the evidence. The only dated information is the EC number 680-607-0, which is an identifier, not a change. The ECHA C&L notifications and AICIS listing are current statuses, but no transition periods or upcoming amendments were mentioned. For a launch timeline, you should monitor each market's inventory and notification updates, but the evidence does not indicate any imminent regulatory shifts that would alter the compliance assessment.